Alpha memo: resveratrol exercise protocol mismatch

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• The 'surprising' framing could be slightly softened — Receipt 1 was explicitly a safety/feasibility pilot and did not claim additive efficacy, so the contrast is more about what the receipts do/don't claim than about a true reversal.
• Receipt 2 is from 2014, outside the typical 5-year recency window, but this is acceptable given it is the canonical matched RCT and the memo is explicitly a contrast between two fixed receipts.

Reviewer note

The memo delivers exactly what an alpha-memo should: one bounded signal (context-dependent null of resveratrol additivity on molecular mitochondrial endpoints despite feasibility of the combination in a functionally limited cohort), grounded in two receipt-matched RCTs. Receipt 1 (Harper et al. 2021, Exp Gerontol, N=60, 71.8±6.3 y, 500–1000 mg/day, 12 wk, functionally limited adults) is accurately described as a safety/feasibility pilot of the combination, and Receipt 2 (Olesen et al. 2014, J Physiol, healthy inactive men 60–72 y, 250 mg/day, 8 wk) is accurately described as reporting exercise-only effects on PGC-1α mRNA, cytochrome c, COX-I, citrate synthase, and 3-HAD. The exact fold-changes reported in the memo align with the abstract excerpt in the source bundle. Title/source alignment is clean: the memo is explicitly titled as a 'resveratrol exercise protocol mismatch,' and both receipts concern resveratrol ± exercise in older adults, so the title anchor matches the evidence bundle. The caveat list is strong — it names the specific confounders (sex, dose, duration, baseline functional status, sample size) rather than offering generic hedging, and the falsifier clause specifies the exact moderator-isolating trial that would invalidate the context-dependence reading. Gaps are concrete and actionable (matched-dose crossover, functionally limited vs. healthy inactive stratification). No clinical, policy, or investment claims are made; the bounded conclusion that additivity may depend on baseline functional status is appropriately tentative. Accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis